996 related articles for article (PubMed ID: 17582921)
1. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
[TBL] [Abstract][Full Text] [Related]
2. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
Hantz S; Alain S; Denis F
Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus (HPV) vaccines: a Canadian update.
Foerster V; Murtagh J
Issues Emerg Health Technol; 2007 Dec; (109):1-8. PubMed ID: 18062141
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus quadrivalent vaccine: a look behind the numbers.
Flaherty DK; Alkhateeb FM
Ann Pharmacother; 2009 Apr; 43(4):740-4. PubMed ID: 19276314
[TBL] [Abstract][Full Text] [Related]
5. Papillomavirus vaccine types 16 and 18: new drug. Cervical cancer: just another vaccine.
Prescrire Int; 2008 Jun; 17(95):103-4. PubMed ID: 18623911
[TBL] [Abstract][Full Text] [Related]
6. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.
Garland SM; Steben M; Sings HL; James M; Lu S; Railkar R; Barr E; Haupt RM; Joura EA
J Infect Dis; 2009 Mar; 199(6):805-14. PubMed ID: 19199546
[TBL] [Abstract][Full Text] [Related]
7. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.
Harper DM
Public Health Genomics; 2009; 12(5-6):319-30. PubMed ID: 19684444
[TBL] [Abstract][Full Text] [Related]
8. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
9. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.
Syrjänen KJ
Scand J Infect Dis Suppl; 2009; 107():3-32. PubMed ID: 19408160
[TBL] [Abstract][Full Text] [Related]
10. Introducing human papillomavirus vaccines - questions remain.
Paavonen J; Lehtinen M
Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882
[TBL] [Abstract][Full Text] [Related]
11. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
[TBL] [Abstract][Full Text] [Related]
12. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
13. [Cervical cancer prevention: the impact of HPV vaccination].
Monsonégo J
Gynecol Obstet Fertil; 2006 Mar; 34(3):189-201. PubMed ID: 16529969
[TBL] [Abstract][Full Text] [Related]
14. [Value of general human papillomavirus vaccination in sexually active women].
Hampl M
Dtsch Med Wochenschr; 2009 Apr; 134 Suppl 2():S95-9. PubMed ID: 19353480
[TBL] [Abstract][Full Text] [Related]
15. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
[TBL] [Abstract][Full Text] [Related]
16. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
[TBL] [Abstract][Full Text] [Related]
17. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
18. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.
Villa LL; Ault KA; Giuliano AR; Costa RL; Petta CA; Andrade RP; Brown DR; Ferenczy A; Harper DM; Koutsky LA; Kurman RJ; Lehtinen M; Malm C; Olsson SE; Ronnett BM; Skjeldestad FE; Steinwall M; Stoler MH; Wheeler CM; Taddeo FJ; Yu J; Lupinacci L; Railkar R; Marchese R; Esser MT; Bryan J; Jansen KU; Sings HL; Tamms GM; Saah AJ; Barr E
Vaccine; 2006 Jul; 24(27-28):5571-83. PubMed ID: 16753240
[TBL] [Abstract][Full Text] [Related]
19. [Human papillomavirus and carcinoma of the cervix vaccines against the human papillomavirus-promise of an efficacious prevention].
Kohl I
Klin Mikrobiol Infekc Lek; 2006 Jun; 12(3):91-7. PubMed ID: 17051469
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]